While somatotropinomas primarily express both SSTR2 and SSTR5, which mediate their response to first-generation somatostatin analogs or Pasiroetide, the expression profile in corticotroph tumors is more heterogeneous and involves a predominant expression of SSTR5 [20,68,69]. The gene discussed is SSTR5; the disease is growth hormone-producing pituitary gland neoplasm.